Home
    Disclaimer
    2C-F molecular structure

    2C-F Stats & Data

    NPS DataHub
    MW199.23
    FormulaC10H14FNO2
    CAS207740-15-6
    IUPAC2-(4-fluoro-2,5-dimethoxyphenyl)ethanamine
    SMILESNCCc1cc(OC)c(F)cc1OC
    InChIKeyQAVFEDRVOUKIPM-UHFFFAOYSA-N
    Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic
    Half-Life Unknown (no human pharmacokinetic studies)

    Pharmacology

    DrugBank

    Description

    At a dose of 250 milligrams, 2C-F produces modest closed-eye visuals accompanied by lethargy.

    Mechanism of Action

    Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-F.

    Effect Profile

    Curated
    Psychedelic 5.8

    Strong visuals with moderate body load, mild headspace

    Visual Intensity×3
    10
    Headspace Depth×3
    4
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    6

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown (no human pharmacokinetic studies)
    Addiction Potential
    Low; no evidence of physiologic dependence or compulsive use. Tends to be self‑limiting due to mild effects even at high doses and body‑load at the upper range.

    Tolerance Decay

    Full tolerance 6h Half tolerance 3d Baseline ~14d

    Model extrapolated from general serotonergic psychedelic tolerance patterns and reports for 2C‑B/2C‑T series; no direct PK/PD data for 2C‑F.

    Cross-Tolerances

    LSD
    50% ●○○
    Psilocybin
    50% ●○○
    Other 2C‑x phenethylamines
    70% ●●○
    Lysergamides (e.g., 1P‑LSD)
    50% ●○○

    Harm Reduction

    drugs.wiki

    Identity and potency uncertainty is the primary harm‑reduction issue: 2C‑F is rare and reported as barely active; in grey markets it may be mis‑sold as other 2C‑x or even NBOMe/DOx compounds that are active at milligram or microgram levels. Use reagent kits as a first pass and, where available, submit to a lab drug‑checking service; do not escalate doses until identity is confirmed. Large single doses (hundreds of milligrams) raise cardiovascular strain (tachycardia, blood pressure) typical of phenethylamines; avoid stimulants, overheated venues, and dehydration. Onset can be delayed and subtle; redosing too early is a common cause of accidental over‑intoxication—wait at least 3–4 hours before considering any increase. Avoid lithium entirely: combinations with serotonergic psychedelics have precipitated seizures and severe reactions. Avoid tramadol/bupropion and MAOIs due to seizure and serotonergic risks. Tolerance to serotonergic psychedelics develops rapidly and decays over ~1–2 weeks; stacking trips compresses sleep, raises anxiety, and blunts subsequent responses. Because clinical pharmacokinetics are unknown, those with cardiovascular disease, epilepsy, or significant psychiatric comorbidity should abstain; if someone becomes overheated or confused, prioritize cooling, hydration with electrolytes, a calm environment, and seek medical help for chest pain, severe agitation, or seizures.

    ← Back to 2C-F